HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Costs and outcomes associated with colfosceril versus beractant for the treatment of neonatal respiratory distress syndrome.

AuthorsL Wyble, M L Santeiro
JournalThe Annals of pharmacotherapy (Ann Pharmacother) Vol. 31 Issue 6 Pg. 787-8 (Jun 1997) ISSN: 1060-0280 [Print] United States
PMID9184726 (Publication Type: Comparative Study, Letter)
Chemical References
  • Biological Products
  • Drug Combinations
  • Fatty Alcohols
  • Pulmonary Surfactants
  • Phosphorylcholine
  • Polyethylene Glycols
  • dipalmitoylphosphatidylcholine, hexadecanol, tyloxapol drug combination
  • beractant
Topics
  • Biological Products
  • Drug Combinations
  • Drug Costs
  • Fatty Alcohols (economics, therapeutic use)
  • Humans
  • Infant, Newborn
  • Phosphorylcholine
  • Polyethylene Glycols (economics, therapeutic use)
  • Pulmonary Surfactants (economics, therapeutic use)
  • Respiratory Distress Syndrome, Newborn (drug therapy, economics)
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: